Surgical patients may still have leftovers in their system even after a standard fast, potentially increasing the chance of a serious complication.
KELOWNA, BC / ACCESS Newswire / January 30, 2025 / Lexaria Bioscience Corp. , (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this annual letter from ...
With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...
Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...
A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...
Kournikova, who stays mostly out of the spotlight, has been with singer Enrique Iglesias since 2001. President Trump and Elon ...
A damaging trial failure in December wiped 70% off the share price of BioAge Labs, a US biopharma developing therapeutic ...
Telehealth company Hims & Hers is playing offense in a new commercial slated to air during the Super Bowl next month. | Telehealth company Hims & Hers is playing offense in a new commercial slated to ...
Hims & Hers may leverage FDA compounding exemptions to further extend its compounded GLP-1 offerings. Learn why HIMS stock is ...
Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.
The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...
Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...